CART-19

Phase 2Cell therapy

UUniversity of Pennsylvania

CART-19 is one of 201 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Acute LeukemiaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Acute LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CART-19

UUniversity of Pennsylvania

Phase 2

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Acute Leukemia

NCT06101381

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Completed·UUniversity of Pennsylvania·Phase 2·NCT02030847·42 enrolled

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Unknown status·BBeijing Sanwater Biological Technology Co., Ltd.·Phase 1·NCT02810223·20 enrolled

CAR2 trials

CART-19 Cells For MRD Positive CD19+ ALL

Unknown status·FFujian Medical University·Phase 2/3·NCT03027739·20 enrolled

Allo CART-19 Protocol

Terminated·UUniversity of Pennsylvania·Phase 1·NCT01551043·2 enrolled

Leukemia2 trials

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Completed·UUniversity of Pennsylvania·Phase 1·NCT01029366·26 enrolled

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Completed·UUniversity of Pennsylvania·Phase 1/2·NCT01626495·73 enrolled

Lymphoma2 trials

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Completed·UUniversity of Pennsylvania·Phase 2·NCT02030834·63 enrolled

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 1·NCT03101709·30 enrolled

Chronic Lymphocytic Leukemia1 trial

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

Terminated·UUniversity of Pennsylvania·Phase 1·NCT02640209·20 enrolled

6 more indications

Minimal Residual Disease1 trial

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Terminated·UUniversity of Pennsylvania·Phase 2·NCT02935543·1 enrolled

Acute Myeloid Leukemia1 trial

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Unknown status·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1/2·NCT03896854·15 enrolled

T Cells1 trial

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Completed·UUniversity of Pennsylvania·Phase 2·NCT01747486·42 enrolled

Multiple Myeloma1 trial

CART-19 for Multiple Myeloma

Completed·UUniversity of Pennsylvania·Phase 1·NCT02135406·13 enrolled

Acute Leukemia1 trial

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Recruiting·UUniversity of Sao Paulo·Phase 1/2·NCT06101381·81 enrolled

Cytokine Release Syndrome1 trial

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Completed·UUniversity of Pennsylvania·Phase 1·NCT02906371·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for CART-19. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CART-19 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CART-19. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Pennsylvania

CART-19

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

CAR2 trials

Leukemia2 trials

Lymphoma2 trials

Chronic Lymphocytic Leukemia1 trial

Minimal Residual Disease1 trial

Acute Myeloid Leukemia1 trial

T Cells1 trial

Multiple Myeloma1 trial

Acute Leukemia1 trial

Cytokine Release Syndrome1 trial

References

Drug Info

Quick Facts

Related News